Can-fite Biopharma Ltd. income statement

In fiscal 2025, Can-fite Biopharma Ltd. reported revenue of $405,000, down 39.9% on the year before, operating income of −$9.9m (a -2456.8% margin) and net income of −$9.8m, or −$11.94 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Can-fite Biopharma Ltd.: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	4	2	1	1	1	1	1	0
Research and development	6	11	12	10	8	6	6	7
Selling, general and administrative	—	—	0	0	0	—	—	—
General and administrative	3	3	—	—	—	3	3	4
Operating income	−5	−12	−14	−13	−10	−8	−8	−10
Interest expense	—	—	—	—	−0	1	0	0
Net interest income	−1	−1	−0	0	−0	—	—	—
Income before tax	−7	−13	−14	−13	−10	−8	−8	−10
Net income	−7	−13	−14	−13	−10	−8	−8	−10
Diluted EPS	−$0.09	−$0.07	−$0.08	—	—	−$35.84	−$21.72	−$11.94
Diluted shares (average)	78m	172m	179m	277m	408m	—	—	—
EBITDA	−5	−12	−14	−13	−10	−8	−8	−10

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CANF vs CRVO CANF vs CRDF CANF vs CLNN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Can-fite Biopharma Ltd.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Can-fite Biopharma Ltd.